High-performance liquid chromatographic method for the simultaneous measurement of remacemide (a novel anticonvulsant and cerebroprotectant) and an active metabolite in human plasma.
A high-performance liquid chromatographic (HPLC) method was developed and validated for the determination of both remacemide (a novel anticonvulsant and cerebroprotectant) and an active, major metabolite in human plasma. After the addition of an internal standard, the analytes were extracted from the plasma by ion-exchange solid-phase extraction and measured by an isocratic HPLC system with ultraviolet detection at 210 nm. The recovery of the analytes was > 90%. The standard curves were linear over the range of quantitation of approximately 10-500 ng/ml for remacemide itself and 15-250 ng/ml for the metabolite. Both intra-day and inter-day accuracy and precision data were excellent. Remacemide and its metabolite were shown to be stable in human plasma for at least a year when stored at -20 degrees C.
Flynn
J W
JW
Department of Chemistry, Fisons Pharmaceuticals, Rochester, NY 14603-1710.
O'Brien
J E
JE
D000081:Acetamides / Q000097:blood*; D000927:Anticonvulsants / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D002852:Chromatography, Ion Exchange; D006801:Humans; D007202:Indicators and Reagents; D013056:Spectrophotometry, Ultraviolet
D000081:Acetamides; D000927:Anticonvulsants; D007202:Indicators and Reagents; C067553:remacemide